Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program

Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program
21 June 2016 pulse

Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program

Saint Prex, Switzerland – 21 June 2016 –

The Ferring Innovation Grants Program, which is now open for applications, has been significantly expanded as part of Ferring’s continued commitment to investing in research and development (R&D).

An initiative of the Ferring Research Institute (FRI), the program provides annual grants of up to $100,000 for early stage research, with a focus on novel extracellular drug targets addressable with peptides or proteins within Ferring’s core therapeutic areas: reproductive health, gastroenterology, urology, and endocrinology.

Total funding for this year’s program has been increased from $250,000 to $950,000. Together with changes to the application process and grants structure, this will open up the program to more applicants from leading research centres.

“The Innovation Grants Program is part of our broader commitment to stimulating basic research, with the ultimate aim of developing innovative products that improve the lives of patients,” said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals.

“It’s tremendous to be able to tap into the wider research community for new ideas,” said Keith James, President of FRI and Senior Vice President, Research and Development. “The program gives us a powerful window on external innovation in
our therapeutic areas of interest.”

For more information on this year’s program, please visit: www.ferring-research.com/ferring-grants

– ENDS –

About Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

To learn more about Ferring or its products please visit www.ferring.com

For more information, please contact

Helen Gallagher
Corporate Communications
+41 58 301 00 51

Nicole Barraud-Estoppey
Corporate Communications
+41 58 301 00 53

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.


Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.


Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals


Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.


Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.


Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.